SCHEMBL4232133

SCHEMBL4232133

Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1C(=O)NCc1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AR P10275 17/20 0.63
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.49
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4232821 0.91 AR (0.58) ARCNR1
SCHEMBL4242145 0.91 AR (0.61) AR
SCHEMBL4227409 0.90 NPC1 (0.57) ARALDH1A1CNR1
SCHEMBL4243205 0.90 AR (0.68) ARCNR1
SCHEMBL4236448 0.90 CNR1 (0.59) ARCNR1
SCHEMBL4235512 0.90 AR (0.56) AR
SCHEMBL4231171 0.89 AR (0.69) ARCNR1
SCHEMBL4303028 0.88 AR (0.60) ARCNR1
SCHEMBL4303521 0.86 AR (0.55) ARCNR1
SCHEMBL4231303 0.85 AR (0.62) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 AR 622/4885ALDH1A1 1105/4885TP53 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.